



REMARKS

In response to the Examiner's restriction requirement, applicants elect the compounds of Group II, claims 1-8, 10, 14-16 and 25-28, drawn to compounds of formula I wherein $m = 1$ and $n = 2$, corresponding composition and method of use, and, for the single elected species, applicants elect 4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane. Applicants' election is made with traverse. It is submitted that invention Groups I-VI are all related to the same underlying class of compounds and therefore it would not pose an undue burden to the Examiner to examine all of the Groups.

Accordingly, for this reason, Applicants request reconsideration and withdrawal of the Restriction Requirement set forth in the Office Action of October 5, 2005.

Applicants reserve the right to file divisional or continuation applications directed to the non-elected subject matter.


If a telephone interview would be of assistance in advancing the prosecution of the subject application, the Examiner is kindly invited to telephone applicants' undersigned attorney at the telephone number provided.

No fee is believed necessary in connection with filing this Amendment. However, if any additional fee is found necessary in connection with filing this Amendment, authorization is hereby given to charge such fee to Deposit Account No. 16-1445.

A favorable response is earnestly solicited.

Date: November 7, 2005

Respectfully submitted,



Jason G. Tebbutt
Attorney for Applicant(s)
Reg. No. 55,671

A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-4827